Iterum Therapeutics plc (NASDAQ:ITRM – Get Rating) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 2,670,000 shares, a drop of 24.8% from the March 31st total of 3,550,000 shares. Currently, 1.5% of the company’s shares are sold short. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio is currently 1.9 days.
Separately, Zacks Investment Research lowered shares of Iterum Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 5th.
NASDAQ:ITRM opened at $0.25 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.43 and a quick ratio of 6.43. The firm has a market cap of $46.39 million, a price-to-earnings ratio of -0.33 and a beta of 1.08. The company’s fifty day simple moving average is $0.35. Iterum Therapeutics has a twelve month low of $0.25 and a twelve month high of $2.52.
Several large investors have recently bought and sold shares of the stock. Morgan Stanley lifted its holdings in shares of Iterum Therapeutics by 700.4% during the 3rd quarter. Morgan Stanley now owns 456,410 shares of the company’s stock valued at $255,000 after acquiring an additional 399,385 shares in the last quarter. Virtu Financial LLC acquired a new position in Iterum Therapeutics in the 4th quarter worth $164,000. Franklin Resources Inc. acquired a new position in Iterum Therapeutics in the 3rd quarter worth $215,000. Geode Capital Management LLC lifted its holdings in Iterum Therapeutics by 27.9% in the 3rd quarter. Geode Capital Management LLC now owns 129,271 shares of the company’s stock worth $72,000 after buying an additional 28,169 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Iterum Therapeutics by 106.9% in the 3rd quarter. Squarepoint Ops LLC now owns 52,503 shares of the company’s stock worth $29,000 after buying an additional 27,121 shares in the last quarter. Institutional investors and hedge funds own 3.32% of the company’s stock.
About Iterum Therapeutics (Get Rating)
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
- Get a free copy of the StockNews.com research report on Iterum Therapeutics (ITRM)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.